Diabetic Kidney Disease

The contract between this chapter and the reader.

1. 1. Recognise diabetic kidney disease as the leading cause of ESKD.
2. 2. Explain its mechanism and natural history.
3. 3. Diagnose it clinically and know when to biopsy.
4. 4. Apply the modern pillars of treatment (SGLT2, RAAS, finerenone, GLP-1).
5. 5. Recognise and diagnose renal amyloidosis.
6. 6. Type and treat amyloidosis by its cause.
7. 7. Identify the other secondary nephrotic causes.
8. 8. Distinguish non-immune from immune nephrotic disease.
9. 9. Appraise the evidence behind modern diabetic-kidney-disease therapy.

A sixty-second reading. Each bullet stands alone.

• Diabetic kidney disease is the commonest cause of end-stage kidney disease worldwide.
• It arises from chronic hyperglycemia causing hyperfiltration and metabolic injury, with nodular glomerulosclerosis.
• It progresses through hyperfiltration, microalbuminuria, overt nephropathy, and declining GFR.
• It is usually diagnosed clinically — long-standing diabetes, retinopathy, a typical course, and a bland sediment.
• Biopsy is reserved for atypical features suggesting a superimposed glomerulonephritis.
• SGLT2 inhibitors provide kidney and cardiovascular protection and are foundational therapy.
• RAAS blockade reduces proteinuria and slows progression.
• Finerenone, a nonsteroidal mineralocorticoid antagonist, reduces progression and cardiovascular events.
• GLP-1 receptor agonists add glycemic and emerging kidney benefit.
• Renal amyloidosis is a deposition disease of misfolded protein fibrils causing nephrotic syndrome.
• Amyloid is diagnosed by Congo-red staining and typed as AL or AA, then treated by its cause.
• The non-immune nephrotic diseases (diabetic, amyloid) are treated metabolically, not with immunosuppression.
• Modern therapy layers RAAS blockade, SGLT2 inhibition, finerenone, and GLP-1 agonists on glycemic and blood-pressure control.

The medical core. An expert should agree diabetic kidney disease and the other nephrotic causes are fully covered here.

Why it matters at the bedside

Diabetic kidney disease is the giant of nephrology — the single commonest road to dialysis on Earth — and for decades the most we could offer was to slow it. That has changed: a stack of new drugs now genuinely protects the diabetic kidney. This chapter is about that transformation, and about the other, non-immune nephrotic diseases — amyloid and its kin — that the podocytopathy chapters leave out.

Diabetic kidney disease: the scale of it

• Diabetic kidney disease is the leading cause of end-stage kidney disease worldwide, the final destination for a large fraction of patients on dialysis and waiting lists. It is a disease of numbers and of time — the cumulative toll of years of hyperglycemia on the glomerulus — and its sheer prevalence is what makes its prevention and treatment so consequential.

The mechanism

• Chronic hyperglycemia injures the glomerulus through two interlocking routes: a hemodynamic one — early hyperfiltration and raised intraglomerular pressure — and a metabolic one — advanced glycation end-products and related pathways. The result is mesangial expansion, basement-membrane thickening, the characteristic Kimmelstiel-Wilson nodular glomerulosclerosis, and podocyte loss, producing progressive albuminuria and falling function. It is the archetypal non-immune glomerular disease.

The natural history

• The course is stereotyped: an early hyperfiltration phase with a raised GFR, then microalbuminuria (the first clinical marker), then overt nephropathy with macroalbuminuria, and finally a declining GFR toward end-stage disease. Recognising the stage matters because intervention is most effective early, and the trajectory — typically slow and predictable — is itself a diagnostic clue.

Diagnosis and when to biopsy

• Diabetic kidney disease is usually a clinical diagnosis: long-standing diabetes, diabetic retinopathy (especially in type 1), a typical slow course, and a bland sediment together make a biopsy unnecessary. Biopsy is reserved for atypical features that suggest a superimposed glomerulonephritis — an active sediment, absent retinopathy, a rapid change in function, heavy proteinuria of abrupt onset, or a short diabetes duration — the deferral principle established in the approach chapter.

The modern pillars of treatment

• Treatment has been transformed into a layered, evidence-based stack — the ‘pillars’. RAAS blockade (an ACE inhibitor or ARB) reduces proteinuria and slows progression; SGLT2 inhibitors are now foundational, conferring both kidney and cardiovascular protection; finerenone, a nonsteroidal mineralocorticoid-receptor antagonist, further reduces progression and cardiovascular events; and GLP-1 receptor agonists add glycemic control and emerging kidney benefit. These are layered on the foundation of glycemic control, blood-pressure control, statins, and lifestyle — the largest therapeutic advance nephrology has seen in a generation.

Renal amyloidosis

• Amyloidosis is the prototype deposition disease: misfolded proteins aggregate into insoluble fibrils that infiltrate the glomeruli and vessels, producing nephrotic syndrome and multi-organ disease. The two renal-relevant types are AL amyloid (immunoglobulin light chains, from a plasma-cell dyscrasia or myeloma) and AA amyloid (serum amyloid A, from chronic inflammation). It is a non-immune nephrotic disease whose treatment targets the source of the protein.

Typing and treating amyloid

• Diagnosis rests on Congo-red staining — the deposits show the classic apple-green birefringence under polarised light — followed by typing (AL versus AA, by immunohistochemistry or mass spectrometry) and a search for the source (serum and urine light chains, marrow for AL; the inflammatory cause for AA). Treatment is cause-directed: anti-plasma-cell therapy for AL, control of the inflammation for AA — not immunosuppression of the kidney itself.

Other secondary nephrotic causes

• Beyond diabetic and amyloid disease, the nephrotic differential includes other deposition and metabolic processes — monoclonal light-chain deposition disease and the secondary forms of the diseases already covered (secondary FSGS from hyperfiltration, membranous from malignancy or hepatitis). The point is that ‘nephrotic syndrome’ spans immune and non-immune causes, and the distinction is everything for treatment.

Non-immune versus immune nephrotic disease

• This is the chapter's organising contrast. The podocytopathies (minimal change, primary FSGS) and immune-complex membranous are immune diseases treated, when appropriate, with immunosuppression. Diabetic kidney disease and amyloid are non-immune — metabolic and deposition diseases — treated by metabolic and cause-directed therapy, never by immunosuppression. Mislabelling a non-immune nephrotic disease as immune, and immunosuppressing it, is a serious and avoidable error.

The evidence and the SGLT2 era

• The modern evidence base is exceptional: SGLT2 inhibitors slow progression and reduce cardiovascular and kidney events across large trials (CREDENCE, DAPA-CKD, EMPA-KIDNEY); RAAS blockade has long-established benefit; finerenone reduces progression and cardiovascular events (FIDELIO-DKD, FIGARO-DKD); and GLP-1 agonists are now showing kidney benefit (FLOW). Layered together, these have turned diabetic kidney disease from an inexorable march to dialysis into a genuinely modifiable condition — the defining therapeutic story of contemporary nephrology.

Five fully-built tables.

Table A — Diabetic kidney disease overview

Table B — Natural history and the biopsy question

Table C — The treatment pillars

Table D — Amyloidosis

Table E — The nephrotic differential

Visualise & Map

Causal chains, each ending in a named action.

Chain 1 — The diabetic glomerulus

Chronic hyperglycemia → hyperfiltration and advanced glycation → nodular sclerosis and podocyte loss → albuminuria and progressive CKD → ACTION: SGLT2 inhibition plus RAAS blockade.

Chain 2 — The pressure lever

Hyperfiltration → raised intraglomerular pressure → progressive injury → ACTION: lower the pressure (RAAS blockade and SGLT2 inhibition).

Chain 3 — The atypical clue

Active sediment / absent retinopathy / rapid change → the picture is not typical diabetic disease → a superimposed glomerulonephritis is possible → ACTION: biopsy.

Chain 4 — The deposited fibril

Misfolded protein → insoluble amyloid fibrils → glomerular deposition → nephrotic syndrome → ACTION: stain Congo red, type the amyloid, and treat its cause.

Chain 5 — The wrong drug

Diabetic and amyloid disease are non-immune → immunosuppression cannot help and only harms → ACTION: treat metabolically or the cause, never with immunosuppression.

Numbered rules. These numbers are the cross-reference handle for the cases and flowcharts.

Clinical Reasoning

Five cases. Each stops you at a decision before it answers it.

Every mechanism from Level 3 earns a bedside consequence and an action.

Exhaustive. Every rule in the chapter is here.

Safety & Evidence

Panel A — Red flags

Panel B — NEVER DO

Anti-patterns clinicians fall into. Each becomes a Level 22 distractor.

The grade reflects strength of evidence, not importance.

Patient Decisions

Outcomes as natural frequencies. Figures are representative; the direction of effect is given where precise numbers are uncertain.

Apply & Test

Copy-paste chart notes that map to the real decisions in this chapter.

Template 1 — Diabetic kidney disease / pillars note

• Diabetes duration; retinopathy; albuminuria; GFR trajectory; sediment ___.
• Diagnosis: clinical (typical) vs biopsy considered (atypical features) ___.
• Foundation: glycemia, blood pressure, lipids, lifestyle ___.
• Pillars: RAAS blockade; SGLT2 inhibitor; finerenone; GLP-1 agonist ___.
• Residual albuminuria and next layer: ___.

Template 2 — Amyloid / atypical-feature note

• Atypical features prompting biopsy (active sediment, no retinopathy, rapid change): ___.
• Congo red / birefringence; amyloid type (AL vs AA): ___.
• Source workup: serum/urine light chains; marrow; inflammatory cause ___.
• Treatment of the underlying cause: ___.
• Non-immune confirmed — immunosuppression withheld: ___.

Pre-rounds compression. Rules only.

Active recall. At least one card per objective.

Micro-teaching for rounds. Two scenarios, five steps each.

Metacognition anchored to this chapter's tensions. No answers provided.

1. 1. The diabetic biopsy threshold trades the risk of the procedure against the chance of finding a treatable superimposed disease; how do you set it for the patient in front of you?
2. 2. Four pillars each add benefit, but also cost, burden, and side-effects; how do you decide how high to build the stack for a given patient?
3. 3. SGLT2 inhibitors cause an early, expected dip in GFR; how do you hold your nerve through a beneficial drug's alarming-looking early effect?
4. 4. Amyloid is easy to miss because it hides in a common syndrome; what keeps Congo red on your mind when the presentation looks ordinary?
5. 5. The greatest harm here is immunosuppressing a non-immune disease; what systems would make you reliably ask ‘immune or not?’ before reaching for steroids?

Nine items, each anchored in this chapter. At least one per objective.